Pulmonary function and autoantibodies in a long-term follow-up of juvenile dermatomyositis patients

Rheumatology (United Kingdom)

Volumn 53, Issue 4, 2014, Pages 644-649

  Mathiesen, Pernille R ^a   Buchvald, Frederik ^b   Nielsen, Kim G ^b   Herlin, Troels ^c   Friis, Tina ^d   Nielsen, Susan ^b  

^a Holbaek University Hospital   (Denmark)

^b Rigshospitalet   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d STATENS SERUM INSTITUT   (Denmark)

Author keywords

Follow up; Juvenile dermatomyositis; Myositis associated autoantibodies; Myositis specific autoantibodies; Pulmonary damage

Indexed keywords

AUTOANTIBODY; EJ ANTIBODY; JO 1 ANTIBODY; MI 2 ANTIBODY; OJ ANTIBODY; PL 12 ANTIBODY; PL 7 ANTIBODY; SRP ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ASSESSMENT; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLOBAL DAMAGE ASSESSMENT; HUMAN; INTERSTITIAL LUNG DISEASE; JUVENILE DERMATOMYOSITIS; LONG TERM CARE; LUNG FUNCTION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MYOSITIS; MYOSITIS ASSOCIATED AUTOANTIBODY; MYOSITIS DAMAGE BY VISUAL ANALOGUE SCALE; MYOSITIS DAMAGE INDEX; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; ORGAN SYSTEMS; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SPIROMETRY; VISUAL ANALOG SCALE;

FOLLOW-UP; JUVENILE DERMATOMYOSITIS; MYOSITIS-ASSOCIATED AUTOANTIBODIES; MYOSITIS-SPECIFIC AUTOANTIBODIES; PULMONARY DAMAGE;

ADOLESCENT; ADULT; ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DERMATOMYOSITIS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; RIBONUCLEOPROTEINS; SEVERITY OF ILLNESS INDEX; SPIROMETRY; VITAL CAPACITY; YOUNG ADULT;

EID: 84897841426     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket380     Document Type: Article

References (22)

1. Feldman BM, Rider LG, Reed AM et al. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008;371:2201-12.
2. Morinishi Y, Oh-Ishi T, Kabuki T et al. Juvenile dermatomyositis: clinical characteristics and the relatively high risk of interstitial lung disease. Mod Rheumatol 2007;17:413-7.
3. Lowry CA, Pilkington CA. Juvenile dermatomyositis: extramuscular manifestations and their management. Curr Opin Rheumatol 2009;21:575-80.
4. Trapani S, Camiciottoli G, Vierucci A et al. Pulmonary involvement in juvenile dermatomyositis: a two-year longitudinal study. Rheumatology 2001;40:216-20.
5. Kobayashi I, Yamada M, Takahashi Y et al. Interstitial lung disease associated with juvenile dermatomyositis: clinical features and efficacy of cyclosporin A. Rheumatology 2003;42:371-4.
6. Sanner H, Aalokken TM, Gran JT et al. Pulmonary outcome in juvenile dermatomyositis: a case-control study. Ann Rheum Dis 2011;70:86-91.
7. Rider LG, Miller FW, Targoff IN et al. A broadened spectrum of juvenile myositis. Myositis-specific autoantibodies in children. Arthritis Rheum 1994;37:1534-8.
8. Wedderburn LR, McHugh NJ, Chinoy H et al. HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology 2007;46:1786-91.
9. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
10. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403-7.
11. American Thoracic Society (ATS) guidelines. Standardization of spirometry. Am J Resp Crit Care Med 1995;152:1107-36.
12. Stanojevic S, Wade A, Stocks J et al. Reference ranges for spirometry across all ages: a new approach. Am J Resp Crit Care Med 2008;177:253-60.
13. Ruperto N, Ravelli A, Murray KJ et al. Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology 2003;42:1452-9.
14. Miller FW, Rider LG, Chung YL et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology 2001;40:1262-73.
15. Rider LG, Lachenbruch PA, Monroe JB et al. Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum 2009;60:3425-35.
16. Altman DG. Practical statistics for medical research. 1st edn. Boca Raton, FL: Chapman & Hall/CRC, 1999.
17. Ravelli A, Trail L, Ferrari C et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res 2010;62:63-72.
18. Mathiesen P, Zak M, Herlin T et al. Clinical features and outcome in a Danish cohort of juvenile dermatomyositis patients. Clin Exp Rheumatol 2010;28:782-9.
19. Solomon J, Swigris JJ, Brown KK. Myositis-related interstitial lung disease and antisynthetase syndrome. J Bras Pneumol 2011;37:100-9.
20. Feldman BM, Reichlin M, Laxer RM et al. Clinical significance of specific autoantibodies in juvenile dermatomyositis. J Rheumatol 1996;23:1794-7.
21. Ronnelid J, Barbasso HS, Storfors H et al. Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies. Autoimmun Rev 2009;9:58-61.
22. Ghirardello A, Bendo R, Rampudda ME et al. Commercial blot assays in the diagnosis of systemic rheumatic diseases. Autoimmun Rev 2009;8:645-9.